Eurofins successfully places EUR 300m inaugural Euro bond
November 19 2013 - 1:30AM
Business Wire
Regulatory News:
Eurofins Scientific (Paris:ERF), the global leader in
bioanalytical testing, announces that it has successfully raised
EUR 300m in its inaugural Euro bond issuance. The bonds have a
five-year maturity, and pay an annual interest rate of 3.125%. The
issue was more than three times over-subscribed.
Eurofins intends to use the proceeds of the offering for general
corporate purposes, including the funding of acquisitions and
expansion investments as part of its objective to double revenues
to EUR 2bn by 2017.
Comment from Dr. Gilles Martin, Eurofins CEO: “I am pleased with
the success of our inaugural bond issue, and the confidence that
investors put into Eurofins. Whilst we have decided to exploit the
current favourable interest rates in the market, and secure and
diversify long-term funding, we intend to maintain our disciplined
approach to acquisitions and a strong balance sheet.”
HSBC acted as global coordinator and joint bookrunner for the
transaction, with BNP Paribas, SG CIB and UniCredit Bank as joint
bookrunners.
The bonds are listed on the regulated market of the Luxembourg
stock exchange. The bonds are not registered under the US
Securities Act of 1933 as amended (the “Securities Act”), and may
not be offered or sold in the United States (as such term is
defined in Regulation S under the Securities Act) unless registered
under the Securities Act or pursuant to an exemption from such
registration.
Notes for the editor:
Eurofins – a global leader in bio-analysis
Eurofins Scientific is the world leader in food and
pharmaceutical products testing. It is also number one in the world
in the field of environmental laboratory services and one of the
global market leaders in agroscience, genomics, discovery
pharmacology and central laboratory services.
With 15,000 staff in more than 190 laboratories across 37
countries, Eurofins offers a portfolio of over 100,000 reliable
analytical methods for evaluating the safety, identity,
composition, authenticity, origin and purity of biological
substances and products. The Group provides its customers with
high-quality services, accurate results in time and expert advice
by its highly qualified staff.
Eurofins is committed to pursuing its dynamic growth strategy by
expanding both its technology portfolio and its geographic reach.
Through R&D and acquisitions, the Group draws on the latest
developments in the field of biotechnology and analytical chemistry
to offer its clients unique analytical solutions and the most
comprehensive range of testing methods.
As one of the most innovative and quality oriented international
players in its industry, Eurofins is ideally positioned to support
its clients’ increasingly stringent quality and safety standards
and the expanding demands of regulatory authorities around the
world.
The shares of Eurofins Scientific are listed on the NYSE
Euronext Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA,
Bloomberg ERF FP).
Important disclaimer:
This press release contains forward-looking statements and
estimates that involve risks and uncertainties. The forward-looking
statements and estimates contained herein represent the judgement
of Eurofins Scientific’ management as of the date of this release.
These forward-looking statements are not guarantees for future
performance, and the forward-looking events discussed in this
release may not occur. Eurofins Scientific disclaims any intent or
obligation to update any of these forward-looking statements and
estimates. All statements and estimates are made based on the data
available to the Company as of the date of publication, but no
guarantee can be made as to their validity.
Eurofins Investor RelationsPhone: +32-2-766 1620E-mail:
ir@eurofins.comwww.eurofins.com
Enerplus (NYSE:ERF)
Historical Stock Chart
From Jun 2024 to Jul 2024
Enerplus (NYSE:ERF)
Historical Stock Chart
From Jul 2023 to Jul 2024